# Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

> **NCT02336178** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 70 (actual)

## Conditions studied

- HEMOPHILIA B

## Interventions

- **DRUG:** Benefix

## Key facts

- **NCT ID:** NCT02336178
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-07
- **Final completion:** 2016-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336178, "Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02336178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*